BJMO - volume 13, issue 6, october 2019
W. Lybaert MD, T. Vandamme MD, G. Boons , K. Vandenborne , L. De Backer , M. Peeters MD, PhD
MARCH 6-8TH, 2019, BARCELONA
Read moreBJMO - volume 13, issue 4, june 2019
W. Lybaert MD, H. Prenen MD, PhD, A. Demols MD, PhD, I. Dero MD
At the background of the Golden Gate Bridge with a view on the Pacific Ocean, the annual Gastrointestinal Cancers Symposium was held from 17–19 January 2019 in the Moscone Congress Center in San Francisco, California. The meeting further underlined the invasion of immunotherapy in the treatment landscape of gastrointestinal tumours, both in the upper and lower digestive tract. In addition to immunotherapy, lots of efforts were made in the molecular profiling of gastrointestinal cancers in every possible tumour location, which will hopefully fuel more biomarker-driven medicine in this setting in the near future. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2019;13(4):142–149)
Read moreBJMO - volume 12, issue 5, september 2018
W. Lybaert MD, T. Vandamme MD, G. Boons , T. Rondou , M. Twickler , I. Dero MD, F. van Fraeyenhove MD, L. De Backer , D. Van Genechten , M. Peeters MD, PhD
March 7-9, 2018, Barcelona, Spain.
(BELG J MED ONCOL 2018:12(5):252–262)
Read moreBJMO - volume 12, issue 3, may 2018
W. Lybaert MD, I. Dero MD, M. Peeters MD, PhD
With the background of the famous Golden Gate Bridge and Alcatraz, the annual Gastrointestinal Cancers Symposium was held from 18–20 January 2018 in the Moscone Congress Center in San Francisco, California. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2018:12(3):133–141)
Read moreBJMO - volume 12, issue 2, march 2018
W. Lybaert MD, P. Clement MD, PhD, K. Punie MD, PhD, J. Mebis MD, PhD, M. Renard , H. Wildiers MD, PhD
Chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment in daily clinical practice. Recently, new data on combinations of antiemetic agents became available for the prevention of acute and delayed nausea/vomiting in patients receiving highly and moderately emetogenic chemotherapy. As a result, the leading international cancer societies updated their antiemesis guidelines. This text aims at providing guidance regarding these new regimens in the prophylaxis of chemotherapy-induced nausea and vomiting, with a particular focus on highly emetogenic chemotherapy.
(BELG J MED ONCOL 2018;12(2):51–60)
Read moreBJMO - 12, issue 3, february 2018
B. De Laere , M. Mayrhofer , T. Whitington , P-J. Van Dam , P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, W. Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , N. Beije , I. De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , L. Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , J. Del-Favero , S. Sleijfer , A. Uhlen , J. Yachnin , S. Van Laere PhD, H. Grönberg , J. Lindberg , L. Dirix MD, PhD
BJMO - 12, issue 3, february 2018
T. Vandamme MD, W. Lybaert MD, M. Simoens , W. Demey MD, T. Rondou , P. Abrams , C. Mattelaer , B. Op De Beeck , O. D’Archambeau , G. Roeyen , L. De Backer , Marc Peeters , Steering Committee , NET-specialists
Top
